Breakthru Medicine recently closed a $60M Series A and is not currently seeking funding immediately but would be interested in Series B early discussions. We are interested in talking to pharma partners regarding our non degrader molecular glues platform and our portfolio of novel payload antibody drug conjugates.

We are focused on large patient population solid tumor programs including breast, colorectal, gastric, lung and prostate cancers.

We are not taking vendor or service provider meetings at this time.